核查意见 华泰联合证券有限责任公司 关于广州慧智微电子股份有限公司 使用自有资金支付募投项目人员费用并以募集资金 等额置换的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为广州慧智微电子股份有限公司（以下简称"慧智微"或"公司"）首次公开发 行股票并在科创板上市持续督导阶段的保荐人，根据《证券发行上市保荐业务管 理办法》《科创板上市公司持续监管办法（试行）》《上海证券交易所科创板股票 上市规则》《上市公司募集资金监管规则》等有关规定，对慧智微使用自有资金 支付募集资金投资项目（以下简称"募投项目"）人员费用并以募集资金等额置 换相关事项进行核查，具体核查情况如下： 一、募集资金的基本情况 根据中国证券监督管理委员会《关于同意广州慧智微电子股份有限公司 首次公开发行股票注册的批复》（证监许可〔2023〕462号），并经上海证券 交易所同意，公司首次公开发行人民币普通股（A股）5,430.05万股，每股发行 价格20.92元，本次募集资金总额为人民币113,596.65万元，扣除各项发行费用 人民币10,763.76万元（不含增值税）后，实际募集资金净额为人民币102,832.89 ...

慧智微公告，公司及全资子公司作为实施主体在募集资金投资项目期间，同意先行使用自有资金支付募 投项目人员费用，后续定期从募集资金专户划转等额资金至公司自有资金账户进行置换。该事项已经公 司董事会和监事会审议通过，无需提交股东会审议，且保荐人华泰联合证券有限责任公司对此出具了明 确的核查意见。 ...

Core Viewpoint - Unisoc (紫光展锐) has successfully positioned itself as the fourth largest smartphone chip manufacturer globally, achieving significant growth in market share and revenue through strategic partnerships and product development in the mid-range and low-end markets [3][4][12]. Group 1: Company Background and Development - In March 2023, Unisoc completed its transformation into a joint-stock company, changing its name to 紫光展锐（上海）科技股份有限公司 [2]. - The company has received substantial financial backing, including a credit line of 3.2 billion yuan from a consortium of five major banks and multiple rounds of equity financing totaling 60 billion yuan [2]. - Unisoc was formed through the merger of 展讯通信 and 锐迪科, which were pioneers in GSM and RF chip technology, respectively [5][6]. Group 2: Market Performance and Positioning - In Q1 2025, Unisoc held a 10% share of the global smartphone AP-SoC market, ranking fourth behind MediaTek, Qualcomm, and Apple [2]. - The company achieved a remarkable 14% market share in smartphone chip shipments in 2024, with over 1.6 billion chips shipped, indicating a strong presence in the mid-range and low-end markets [3]. - Unisoc's 5G chip sales surged by 82% year-on-year in 2024, contributing significantly to its overall market share growth [6]. Group 3: Product Innovations and Future Strategies - Unisoc has focused on developing cost-effective 5G solutions, launching its first 5G chip, the Tiger T7510, in 2020, which has been well-received in the market [6]. - The company is diversifying its product offerings by entering new markets such as smart automotive, IoT, and satellite communication, with products like the A7870 automotive chip and V517 5G RedCap chip [7][8][9]. - Unisoc is also making strides in the mid-range market with the introduction of the T9100 processor, aiming to enhance its competitive position against leading chip manufacturers [11].

金十数据6月19日讯，科创板累计已有54家未盈利企业上市。目前已有22家企业上市后实现盈利，还有 32家尚未实现摘"U"。根据《科创成长层指引》要求，上述32家公司将自指引（正式稿）发布之日起纳 入科创成长层。具体来看，32家尚未摘"U"的存量公司包括：泽璟制药、君实生物、前沿生物、青云科 技、和辉光电、精进电动、百济神州、迪哲医药、迈威生物、翱捷科技、亚虹医药、首药控股、海创药 业、云从科技、益方生物、奥比中光、盟科药业、诺诚健华、信科移动、星环科技、裕太微、云天励 飞、天智航、奇安信、寒武纪、亿华通、埃夫特、慧智微、芯联集成、智翔金泰、盛科通信、中巨芯。 （上证报） 32家科创板未盈利公司将纳入科创成长层 ...

母基金研究中心据公开信息统计， 2 0 2 5年5月1日至5月3 1日资讯涉及的募资动态共1 5起，折 合人民币规模合计超过3 0 0 亿元。以下是内容提要与具体资讯。 【内容提要】 01 礼来亚洲基金成功设立第七期生物医药基金 凯易代表领先生物医药风险投资公司礼来亚洲基金（ LAV）完成其第七期美元生命科学基金礼 来亚洲第七期基金（LAV Fu n d VII, L.P.）的募集。该基金以封顶金额最终交割，获得来自全 球各地的各类机构投资者的踊跃认购，包括主权财富基金、养老金、捐赠基金、大家族办公 室、大型企业和母基金。 02 东南大学无锡校友科创转化基金发布 1 . 礼来亚洲基金成功设立第七期生物医药基金 2 . 东南大学无锡校友科创转化基金发布 3 . 静水湖创投首期 FOF基金完成募集设立 4 . 鲁信创投首批登陆债市 "科技板"成功发行5亿元科技创新债券 5 . 中国石化资本成功发行 9亿元科创债 6 . 元禾控股发行科技创新债券 7 . 东方富海科创债落地 8 . 光源创新前沿孵化基金完成首期募资 9 . 祥峰二期天使基金募集收官 重点关注早期科技项目 1 0 . 嘉御资本落子天津 11 . 毅达 ...

重要内容提示： 证券代码：688512 证券简称：慧智微 公告编号：2025-024 广州慧智微电子股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 股东持股的基本情况 本次减持计划实施前，GZPA Holding Limited（以下简称"GZPA"）持有广州 慧智微电子股份有限公司（以下简称"公司"）股份 15,406,333 股，占公司当时股 份总数的 3.34%。前述股份来源于公司首次公开发行股票并上市前持有的股份， 已于 2024 年 5 月 16 日解除限售并上市流通。 减持计划的实施结果情况 公司于 2025 年 2 月 27 日在上海证券交易所网站（www.sse.com.cn）披露了 《广州慧智微电子股份有限公司股东减持股份计划公告》（公告编号：2025-007）。 GZPA 因自身资金需求，计划于上述公告披露之日起 3 个交易日后的 3 个月内通 过集中竞价方式减持公司股份，合计减持不超过 2,303,812 股，合计减持比例不 超过公司股份总数的 0.50% ...

Group 1 - The annual general meeting of Guangzhou Huizhi Microelectronics Co., Ltd. was held on May 30, 2025, with no rejected proposals [2] - The meeting was conducted in accordance with the Company Law and the company's articles of association, combining on-site and online voting methods [2][3] - All current directors and supervisors attended the meeting, ensuring full representation [3] Group 2 - All proposed resolutions, including the 2024 annual report, board work report, supervisory board work report, financial settlement report, and profit distribution plan, were approved [4][5] - The 2025 financial budget, director and supervisor remuneration plans, and the reappointment of the auditing firm for 2025 were also approved [5][6] - The meeting included a separate vote for minority shareholders on specific resolutions to ensure fair representation [6] Group 3 - The meeting was witnessed by Beijing Zhonglun (Guangzhou) Law Firm, confirming that all procedures and voting results were legal and valid [7]

证券代码：688512 证券简称：慧智微 公告编号：2025-023 广州慧智微电子股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 5 月 30 日 （二） 股东会召开的地点：广东省广州高新技术产业开发区科学城科学大道 182 号创新大厦 C2 栋 8 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 普通股股东人数 | 107 | | 2、出席会议的股东所持有的表决权数量 | 111,574,549 | | 普通股股东所持有表决权数量 | 111,574,549 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 24.2151 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

北京市中伦（广州）律师事务所 关于广州慧智微电子股份有限公司 2024 年年度股东会的 法律意见书 致：广州慧智微电子股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）受广州慧智微电子股份 有限公司（以下简称"公司"）委托，指派田维怡律师、蔡金会律师（以下简称"本 所律师"）对公司召开的 2024 年年度股东会（以下简称"本次股东会"）进行见 证。本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司股东会规则》等法律法规及本法律意见书出具日以前已发生或者存在的事 实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验 证，保证本法律意见所认定的事实真实、准确、完整，所发表的结论意见合法、准 确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应的法律责任。 本所律师依据《公司法》《证券法》及《广州慧智微电子股份有限公司章程》 （以下简称"《公司章程》"）《广州慧智微电子股份有限公司股东会议事规则》 （以下简称"《股东会议事规则》"）的规定，对公司本次股东会进行见证并出 具本法律意见书。 为出具本法律意见书，本所律师审查了本所律师认为作为出具本法律意见书 所 ...

Group 1 - The article highlights significant developments in the private equity fund market, focusing on government-guided funds and their strategic importance in regional economic development [3][4]. - The establishment of the "Lhasa City Industry Strong City Mother Fund" with a total scale of 1.5 billion yuan aims to optimize government investment methods and attract more social capital for industrial construction in Lhasa [5]. - Chengdu High-tech Zone is launching a 300 billion yuan industrial development fund plan, including a 10 billion yuan angel mother fund to support early-stage investments in hard technology [6]. Group 2 - The Hunan Jin Fuyuan Industry Guidance Fund is seeking a GP for its aerospace and marine industry sub-fund, focusing on high-quality enterprises in the aerospace and Beidou industry chain [7]. - The establishment of the "Jiangxi Ji'an Science and Technology Innovation Equity Investment Fund" aims to invest in electronic information, artificial intelligence, and new energy materials, with a target scale of 300 million yuan [8]. - The "Hangzhou Intelligent Connected Industry Development Fund" has been established with a scale of 1 billion yuan to promote the development of the intelligent connected vehicle industry [9]. Group 3 - The Fujian Province New Quality Productivity M&A Series Sub-Fund aims for a target scale of 5 billion yuan, focusing on supporting local enterprises and promoting industrial transformation [10]. - The Nanjing Yangtze River Technology Industry Investment Fund is set to invest in key industries in the Jiangbei New Area, with a minimum subscription scale of 300 million yuan [11]. - The establishment of the "Chongqing Beibei Mother Fund" with a total scale of 2 billion yuan aims to invest in emerging industries such as sensors and smart connected vehicles [12]. Group 4 - The "Xiangtou Huaxin Fund" has been established with a total scale of 200 million yuan to support the development of new energy, new materials, and advanced manufacturing industries in Huaihua [21]. - The "Shenzhen Artificial Intelligence Terminal Industry Investment Fund" and "Shenzhen Artificial Intelligence and Embodied Robotics Industry Fund" have been launched to focus on AI-related technologies [23]. - The establishment of the "Tianjin Biomedical Industry Fund" aims to invest in key areas such as nucleic acid drugs and high-end medical devices, supporting the development of the biomedical industry in Tianjin [24].